Karolinska University Hospital
Karolinska University Hospital is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
The SWENOTECA ABC-study: A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer
Sponsor St. Olavs Hospital HF
- Start (EU)
- Latest update
- Estimated end
- Not reported
Mifepristone and Letrozole versus methotrexate for treatment of Ectopic pregnancy - a randomized, controlled non-inferiority trial (MILE)
Sponsor Karolinska Institutet
- Start (EU)
- Latest update
- Estimated end
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
Sponsor Affibody AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC
Sponsor Aarhus University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sponsor Kancera AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Karolinska University Hospital?
The 2026-10-09 snapshot links Karolinska University Hospital to 7 distinct CTIS trials. Recorded services include Clinical monitoring, Laboratory services, Interactive response technology (IRT), Medicinal product management, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Karolinska University Hospital?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Gynecology, Obstetrics. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Karolinska University Hospital conducted?
The linked trials record locations in 19 countries, including Sweden, Denmark, Norway, Germany, Finland. These are trial locations, not confirmed office locations or countries where Karolinska University Hospital delivered services.
What can this page tell me about Karolinska University Hospital's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Karolinska University Hospital. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Karolinska University Hospital